BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24679653)

  • 1. Cefepime monotherapy for febrile neutropenia in patients with lung cancer.
    Saito H; Takahashi K; Okuno M; Saka H; Imaizumi K; Hasegawa Y; Tanikawa Y; Yamamoto M; Taniguchi H; Shindoh J; Suzuki R; Shimokata K;
    J Infect Chemother; 2014 Jun; 20(6):365-9. PubMed ID: 24679653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of cefepime in febrile neutropenic patients with lung cancer.
    Fujita M; Ouchi H; Inoue Y; Inoshima I; Ohshima T; Yoshimura C; Wataya H; Kawasaki M; Tokunaga S; Nakanishi Y;
    J Infect Chemother; 2010 Apr; 16(2):113-7. PubMed ID: 20130951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study.
    Fujita M; Matsumoto T; Inoue Y; Wataya H; Takayama K; Ishida M; Ebi N; Kishimoto J; Ichinose Y;
    J Infect Chemother; 2016 Apr; 22(4):235-9. PubMed ID: 26867793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
    Corapcioglu F; Sarper N; Zengin E
    Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial.
    Kwon KT; Cheong HS; Rhee JY; Wi YM; Ryu SY; Heo ST; Moon CS; Ki HK; Kim KH; Jung CW; Peck KR; Song JH
    Jpn J Clin Oncol; 2008 Jan; 38(1):49-55. PubMed ID: 18203711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
    Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
    J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.
    Bow EJ; Rotstein C; Noskin GA; Laverdiere M; Schwarer AP; Segal BH; Seymour JF; Szer J; Sanche S
    Clin Infect Dis; 2006 Aug; 43(4):447-59. PubMed ID: 16838234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of empiric monotherapy with ceftazidime for low-risk grade IV febrile neutropenia after cytotoxic chemotherapy in cancer patients.
    Chernobelski P; Lavrenkov K; Rimar D; Riesenberg K; Schlaeffer F; Ariad S; Mermershtain W
    Chemotherapy; 2006; 52(4):185-9. PubMed ID: 16675902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefepime vs. cefoperazone/sulbactam in combination with amikacin as empirical antibiotic therapy in febrile neutropenia.
    Ponraj M; Dubashi B; Harish BH; Kayal S; Cyriac SL; Pattnaik J; Ranjith K; Pillai US; Jadhav N; Matta KK; Singh J; Jaffa E; Prakash B
    Support Care Cancer; 2018 Nov; 26(11):3899-3908. PubMed ID: 29774477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia.
    Bucaneve G; Micozzi A; Picardi M; Ballanti S; Cascavilla N; Salutari P; Specchia G; Fanci R; Luppi M; Cudillo L; Cantaffa R; Milone G; Bocchia M; Martinelli G; Offidani M; Chierichini A; Fabbiano F; Quarta G; Primon V; Martino B; Manna A; Zuffa E; Ferrari A; Gentile G; Foà R; Del Favero A
    J Clin Oncol; 2014 May; 32(14):1463-71. PubMed ID: 24733807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cefepime as an empiric treatment of febrile neutropenia in patients after high dose therapy and autologous stem cell transplantation].
    Zikesoá E; Hnátková M; Vacková B; Jedlicková A; Klener P; Trnený M
    Cas Lek Cesk; 2006; 145(5):383-6, 388-9. PubMed ID: 16755776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
    Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
    Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.
    Pereira CA; Petrilli AS; Carlesse FA; Luisi FA; da Silva KV; de Martino Lee ML
    J Microbiol Immunol Infect; 2009 Apr; 42(2):141-7. PubMed ID: 19597646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aztreonam for febrile neutropenia in patients with beta-lactam allergy.
    McCullough BJ; Wiggins LE; Richards A; Klinker K; Hiemenz JW; Wingard JR
    Transpl Infect Dis; 2014 Feb; 16(1):145-52. PubMed ID: 24119095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
    Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
    Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
    Hamidah A; Lim YS; Zulkifli SZ; Zarina AL; Nordiah AJ; Jamal R
    Singapore Med J; 2007 Jul; 48(7):615-9. PubMed ID: 17609821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefepime monotherapy for treatment of febrile neutropenia in children.
    Ariffin H; Ai CL; Lee CL; Abdullah WA
    J Paediatr Child Health; 2006 Dec; 42(12):781-4. PubMed ID: 17096713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevation of serum C-reactive protein predicts failure of the initial antimicrobial treatment for febrile neutropenia with lung cancer.
    Matsumoto T; Fujita M; Hirota T; Takeda S; Hirano R; Uchino J; Harada T; Watanabe K
    J Infect Chemother; 2013 Apr; 19(2):202-7. PubMed ID: 23053498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefepime as empirical monotherapy in febrile patients with hematological malignancies and neutropenia: a randomized, single-center phase II trial.
    Engervall P; Kalin M; Dornbusch K; Björkholm M
    J Chemother; 1999 Aug; 11(4):278-86. PubMed ID: 10465130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefepime versus ticarcillin and clavulanate potassium and aztreonam for febrile neutropenia therapy in high-dose chemotherapy patients.
    Fleming DR; Ziegler C; Baize T; Mudd L; Goldsmith GH; Herzig RH
    Am J Clin Oncol; 2003 Jun; 26(3):285-8. PubMed ID: 12796602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.